Pharming Q1 2024 GAAP EPS $(0.02) Misses $0.01 Estimate, Sales $55.586M Miss $68.425M Estimate
Portfolio Pulse from Benzinga Newsdesk
Pharming (NASDAQ:PHAR) reported Q1 2024 GAAP EPS of $(0.02), missing the $0.01 estimate, and sales of $55.586M, missing the $68.425M estimate. Despite the miss, sales increased 30.66% from the same period last year.
May 08, 2024 | 5:58 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pharming reported a Q1 2024 GAAP EPS of $(0.02), missing estimates, and sales of $55.586M, also missing estimates but showing a 30.66% increase YOY.
Missing both EPS and sales estimates is likely to negatively impact investor sentiment in the short term, despite the year-over-year sales growth. The significant miss in EPS, by 290 percent, and sales, by 18.76 percent, compared to analyst expectations, suggests potential challenges in profitability and growth expectations, which could lead to a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100